CASE REPORT

A maxillary ameloblastic fibrosarcoma tumor: a rare case report from Syria

Amjad Soltany1,2,*, Ghazal Asaad2,3, Rami Daher2,3, Mouhannad Dayoub2,4, Ali Khalil5, and Zuheir Alshehabi2,6

1Department of Plastic and Reconstructive Surgery, Al Mouwasat University Hospital, Faculty of Medicine, Damascus University, Damascus, Syria, 2Cancer Research Centre, Tishreen University, Latakia, Syria, 3Department of Oncology, Faculty of Medicine, Tishreen University, Latakia, Syria, 4Department of Physical and Rehabilitation Medicine, Faculty of Medicine, Tishreen University, Latakia, Syria, 5Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tishreen University, Latakia, Syria, and 6Department of pathology, Faculty of Medicine, Tishreen University, Latakia, Syria

*Correspondence address. Department of Plastic and Reconstructive Surgery, Al Mouwasat University Hospital, Damascus, Syria. Cancer Research Centre-Tishreen University, Syria. Tel: +963-96-551-5977; E-mail: amjad.soltany@gmail.com

Abstract

Ameloblastic fibrosarcoma (AFS) is a rare, aggressive malignant odontogenic tumor. AFS is seen most frequently in second and third decades of life. We are reporting a case of a low grade AFS in a 21-year-old male complaining of a painless swelling in the right side of the maxilla. The patient was treated with surgical excision followed by radiotherapy, which is considered the most effective approach for most of soft tissue sarcomas. AFS has a high-reported recurrence rate (up to 37%); therefore, long-term surveillance for recurrence is crucial.

INTRODUCTION

Ameloblastic fibrosarcoma (AFS) is a rare malignant odontogenic tumor composed of benign epithelium and malignant mesenchyma [1, 2]. It could originate from ameloblastic fibroma (AF) (two-third of the reported AFS cases) or as a malignant tumor (de novo) (one-third of the reported AFS cases). Like the majority of soft tissue sarcoma cases, the etiology of this tumor is still unknown [3]. AFS is most likely seen in second and third decades of life with a wide range (3–89 years). It is distributed equally in both sexes with a slight larger percentage in males [2, 4]. Usually, the mandible is the most affected site; however, in this case, the tumor was found in the maxilla [2]. The treatment of AF usually involves surgical excision with removal of the affected teeth. But in cases of AFS, chemotherapy and radiotherapy could be used as adjuvant therapies although chemotherapy has not been determined clearly in the treatment guideline for AFS [5]. On the other side, the combination of doxorubicin and olaratumab has been permitted as a first-line therapy for patients with advanced soft-tissue sarcoma responding to anthracycline therapy [6]. Recurrence rate of AFS ranges from about 24% to 37% with a reported incidence of distant metastases of 4.5%; therefore, long-term follow-up is crucial [5].
Figure 1: Clinical appearance of the tumor at the time of diagnosis, showing a swelling in the palatine process of maxilla, spreading from the vestibule of the mouth reaching the upper right premolars.

Figure 2: Preoperative orthopantomogram shows the radiolucent area with the calcified lesions in the right hemi-maxilla with resorption in the roots of the upper right premolars.

CASE PRESENTATION

A 21-year-old male patient presented with swelling in the right maxilla (Fig. 1). The patient had noticed this swelling for the first time 5 months ago in the palatine process of maxilla. This swelling has grown larger within these several months and has spread from the vestibule of the mouth reaching the upper right premolars. Orthopantomography revealed a radiolucent area with calcified lesions and resorption in the roots of the mentioned premolars, reaching the root of the canine as shown in (Fig. 2). Neck ultrasound revealed normal findings. Under topical anesthesia, an oval incision was performed. Histo-pathological findings are shown in (Fig. 3). Immunohistochemistry was performed using vimentin, B-cell lymphoma (Bcl-2), p53 and Ki-67. Vimentin was positive, whereas Bcl-2 and p53 were negative; Ki-67 was expressed by 10–15% of the mesenchymal cells (Fig. 4). In view of these histo-pathological and immunohistochemistry findings, a low grade AFS was diagnosed. After that, the patient underwent a right hemi-maxillectomy with clear margins (1.5–2 cm). Vestibular and palatal mucosal flaps were eradicated. The maxillary bone split from the lateral side of the 21st tooth toward the maxillary tuberosity with complete removal of the maxillary sinus up to the orbital floor. Then, antimicrobial gauzes were applied and we left the wound healing by secondary intention (Fig. 5). A second histo-pathological study confirmed the low grade AFS. The anterior and posterior surgical bone margins were focally involved by the tumor; therefore, another surgery was performed to fully remove the tumor. Because of the deep invasion of the tumor, the surgical procedure was followed by radiotherapy. A radiographic follow-up with head and neck computerized tomography after 3 months revealed that there were no metastases to the surrounding lymph nodes. Delayed reconstruction and rehabilitation should be taken into considerations.

Figure 3: Biphasic tumor composed of islands of benign odontogenic epithelium and an abundant malignant mesenchymal component consisted of ovoid and fusiform cells, in addition to plump and spindle stromal cells that show hypercellularity and nuclear polymorphisms associated with cytologic atypia, mitotic figures and anaplasia (hematoxylin-eosin, x40).

Figure 4: Reactivity to immuno-histochemical stains shows: A: positive reactivity to Vimentin in the mesenchymal component. B: negative reactivity to P53. C: negative reactivity to Bcl2. D: Reactivity to Ki67 in the mesenchymal component with a labeling index of 10–15%.
A maxillary ameloblastic fibrosarcoma tumor

DISCUSSION

AFS is a rare malignant odonto-genic tumor. It represents <5% of all odonto-genic tumors [1]. It was first described by Heath in 1887 [4]. To the best of our knowledge, about 100 documented cases of AFS have been reported. The majority of AF cases are seen in young patients, whereas AFS is seen in older patients [4]. The average age of AFS is about 26 years [4]. Clinically, AFS causes intra-oral and/or extra-oral swelling, which was the main symptom in our case [1]. Patients usually complain of a painful facial mass [2]. However, our patient’s mass was painless. Related symptoms may take from few months up to a year to appear obviously causing, sometimes, a facial deformity [4]. In our case, the tumor took about 5 months to reach a big mass. The majority of reported AFS cases have been located in the molar and premolar regions of the mandible [7], whereas in this report, the tumor was found within the maxilla which is considered a rare location.

Due to limited data on this tumor, an accurate treatment guideline is not recommended [7]. Surgical excision with clear and complete margins and long-term follow-up may be the standard management [4]. There is no strong evidence for the impact of adjuvant therapies in primary treatment of AFS [5]. Nevertheless, the patient received an adjuvant radiotherapy, as it may reduce recurrence rate and local invasion of the tumor [7].

Determination of fibrosarcoma malignancy depends on its degree of differentiation (histo-pathologic grading) [6]. And in view of our previously mentioned histo-pathological findings, our tumor’s degree was estimated as low grade. AFS has low potential for distant metastasis (only two reported cases), but a high reported recurrence rate of 37% and a mortality rate of 19% [2, 4]. Histologically, AFS is characterized by benign epithelial islands which are made up of columnar or cuboidal peripheral cells arranged in a palisading form with a malignant mesenchymal component, composed of ovoid and fusiform cells, in addition to plump and spindle stromal cells that show hypercellularity and nuclear polymorphisms associated with cytologic atypia, mitotic figures and anaplasia [1, 2]. Despite AFS has the last mentioned malignant mesenchymal component and a high labeling indices unlike AF, we still consider AF the main differential diagnosis of AFS as both have a biphasic nature and similar-size in the benign epithelial tissue [2, 4]. The diagnosis of tumor malignancy was based on the morphological features and Ki-67 index for cell proliferation (10–15% in our case). AFS immunohistochemistry usually shows positivity for p53 and Bcl-2 unlike then negativity in AF [4, 8, 9], but in our case, the negativity of immuno-staining for p53 and Bcl-2 can be attributed to the low grade nature of the tumor. Later reconstruction may require local or free flaps, cutaneous or mucosal, bone grafts, etc, according to the squeal of excision. Once reconstruction is performed, an implant-based rehabilitation may be performed [1].

CONCLUSION

Because of limited data and rarity of this tumor, an accurate management is still difficult to define. Although surgical
resection is still the mainstream, adjuvant therapies should be into consideration to reduce recurrence and improve survival.

CONFLICT OF INTEREST
None declared.

FUNDING
None.

REFERENCES
1. Hascoet E, Le C’HS, Taugeron F, Bertin H, Longis J, Piot B, et al. Ameloblastic fibrosarcoma of the mandible: case report and literature review. Med Buccale Chir Buccale 2017;23:164–8.
2. Loya-Solís A, González-Colunga KJ, Pérez-Rodríguez CM, Ramírez-Ochoa NS, Cecenas-Falcón L, Barboza-Quintana O. Ameloblastic Fibrosarcoma of the mandible: a case report and brief review of the literature. Case Rep Pathol 2015;2015:1–5.
3. Dangoor A, Seddon B, Gerrand G, Grimer R, Whelan J, Judson l. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res 2016;6:1–26.
4. Khanna JN, Ramaswami R, Thorat K. Ameloblastic fibrosarcoma—a case report. J Oral Maxillofac Surgery, Med Pathol 2020;32:57–60.
5. Al Shetawi H, Alpert EH, Buchbinder D, Urken ML. Ameloblastic Fibrosarcoma of the mandible: a case report and a review of the literature. J Oral Maxillofac Surg 2015;73:1661.e1–7.
6. Augsburger D, Nelson PJ, Kalinski T, Udelnow A, Knösel T, Hofstetter M, et al. Current diagnostics and treatment of fibrosarcoma - perspectives for future therapeutic targets and strategies. Oncotarget 2017;8:104638–53.
7. Pillay RR, Bilski A, Batstone M. Ameloblastic fibrosarcoma arising in the maxilla. Ochsner J 2016;16:143–5.
8. Pontes HAR, Pontes FSC, De Freitas Silva BS, Cury SEV, Fonseca FP, Salim RA, et al. Immunoeexpression of Ki67, proliferative cell nuclear antigen, and Bcl-2 proteins in a case of ameloblastic fibrosarcoma. Ann Diagn Pathol 2010;14:447–52.
9. Khalili M, Shakib PA. Ameloblastic fibrosarcoma of the upper jaw: report of a rare case with long-term follow-up. Dent Res J (Isfahan) 2013;10:112–5.